Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group, the Dutch Initiative on Crohn, Colitis (ICC). van Linschoten RCA, et al. Among authors: de boer nk. Dig Dis Sci. 2024 Apr 9. doi: 10.1007/s10620-024-08410-z. Online ahead of print. Dig Dis Sci. 2024. PMID: 38594435
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK. Verschuren EC, et al. Among authors: de boer nk. Clin Gastroenterol Hepatol. 2016 Jun;14(6):836-842. doi: 10.1016/j.cgh.2015.12.028. Epub 2015 Dec 31. Clin Gastroenterol Hepatol. 2016. PMID: 26748223
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Ponsioen CY, et al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Lancet Gastroenterol Hepatol. 2017. PMID: 28838644 Clinical Trial.
Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D'Haens GR, Bemelman WA, Ponsioen CY; LIR!C study group. de Groof EJ, et al. Gut. 2019 Oct;68(10):1774-1780. doi: 10.1136/gutjnl-2018-317539. Epub 2019 Feb 1. Gut. 2019. PMID: 31233395 Clinical Trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.
Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy.
Ten Bokkel Huinink S, Beelen EMJ, Ten Bokkel Huinink T, Hoentjen F, G L Bodelier A, Dijkstra G, Romberg-Camps M, de Boer NK, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC). Ten Bokkel Huinink S, et al. Among authors: de boer nk, de vries ac. Eur J Gastroenterol Hepatol. 2023 Jan 1;35(1):45-51. doi: 10.1097/MEG.0000000000002474. Epub 2022 Nov 7. Eur J Gastroenterol Hepatol. 2023. PMID: 36468568
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.
Crouwel F, Simsek M, de Boer MA, Mulder CJJ, van Andel EM, Creemers RH, van Asseldonk DP, van Bodegraven AA, Horjus CS, Visschedijk MC, Weusthuis ALM, Seinen ML, Jharap B, van Schaik FDM, Ahmad I, Boekema PJ, Tack GJ, Wormmeester L, Lutgens MWMD, van Boeckel PGA, Gilissen LPL, Kerkhof M, Russel MGVM, Hoentjen F, Bartelink ME, Kuijvenhoven JP, Maljaars JWJ, van Dop WA, Wonders J, van der Voorn MMPJA, Buiter HJC, de Boer NK. Crouwel F, et al. Among authors: de boer nk, de boer ma. J Crohns Colitis. 2023 May 3;17(5):738-745. doi: 10.1093/ecco-jcc/jjac183. J Crohns Colitis. 2023. PMID: 36521000 Free PMC article.
Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.
Simsek M, Schepers F, Kaplan S, van Asseldonk D, van Boeckel P, Boekema P, Dijkstra G, Fidder H, Gisbertz I, Hoentjen F, Jharap B, Kubben F, de Leest M, Meijssen M, Petrak A, van de Poel E, Russel M, van Bodegraven AA, Mulder CJJ, de Boer N. Simsek M, et al. J Crohns Colitis. 2023 Jun 16;17(6):933-942. doi: 10.1093/ecco-jcc/jjad013. J Crohns Colitis. 2023. PMID: 36702552 Free PMC article.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Among authors: de boer nk, de jong dj, de vries ac. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
312 results